Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts
Top Cited Papers
Open Access
- 30 June 2020
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 108 (1), 17-41
- https://doi.org/10.1002/JLB.3COVR0520-272R
Abstract
Clinical evidence indicates that the fatal outcome observed with severe acute respiratory syndrome-coronavirus-2 infection often results from alveolar injury that impedes airway capacity and multi-organ failure-both of which are associated with the hyperproduction of cytokines, also known as a cytokine storm or cytokine release syndrome. Clinical reports show that both mild and severe forms of disease result in changes in circulating leukocyte subsets and cytokine secretion, particularly IL-6, IL-1 beta, IL-10, TNF, GM-CSF, IP-10 (IFN-induced protein 10), IL-17, MCP-3, and IL-1ra. Not surprising, therapies that target the immune response and curtail the cytokine storm in coronavirus 2019 (COVID-19) patients have become a focus of recent clinical trials. Here we review reports on leukocyte and cytokine data associated with COVID-19 disease in 3939 patients in China and describe emerging data on immunopathology. With an emphasis on immune modulation, we also look at ongoing clinical studies aimed at blocking proinflammatory cytokines; transfer of immunosuppressive mesenchymal stem cells; use of convalescent plasma transfusion; as well as immunoregulatory therapy and traditional Chinese medicine regimes. In examining leukocyte and cytokine activity in COVID-19, we focus in particular on how these levels are altered as the disease progresses (neutrophil NETosis, macrophage, T cell response, etc.) and proposed consequences to organ pathology (coagulopathy, etc.). Viral and host interactions are described to gain further insight into leukocyte biology and how dysregulated cytokine responses lead to disease and/or organ damage. By better understanding the mechanisms that drive the intensity of a cytokine storm, we can tailor treatment strategies at specific disease stages and improve our response to this worldwide public health threat.Keywords
Funding Information
- Philadelphia Foundation
- Science and Technology Development Fund (FDCT014/2015/A1, FDCT201/2017/A3, FDCT0056/2019/AFJ)
- University of Macau (MYRG2016-00023-ICMS-QRCM, MYRG2017-00120-ICMS, MYRG2019-00169-ICMS)
- Philadelphia Foundation
- Science and Technology Development Fund (FDCT014/2015/A1, FDCT201/2017/A3, FDCT0056/2019/AFJ)
- Universidade de Macau (MYRG2016‐00023‐ICMS‐QRCM, MYRG2017‐00120‐ICMS, MYRG2019‐00169‐ICMS)
This publication has 143 references indexed in Scilit:
- Cell Host Response to Infection with Novel Human Coronavirus EMC Predicts Potential Antivirals and Important Differences with SARS CoronavirusmBio, 2013
- Innate Immune Response of Human Alveolar Type II Cells Infected with Severe Acute Respiratory Syndrome–CoronavirusAmerican Journal of Respiratory Cell and Molecular Biology, 2013
- Ultrastructural characterization of cystic fibrosis sputum using atomic force and scanning electron microscopyJournal of Cystic Fibrosis, 2012
- Into the Eye of the Cytokine StormMicrobiology and Molecular Biology Reviews, 2012
- Excessive Neutrophils and Neutrophil Extracellular Traps Contribute to Acute Lung Injury of Influenza PneumonitisThe American Journal of Pathology, 2011
- Long-Term Persistence of Robust Antibody and Cytotoxic T Cell Responses in Recovered Patients Infected with SARS CoronavirusPLOS ONE, 2006
- Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndromeRespirology, 2006
- The Involvement of Natural Killer Cells in the Pathogenesis of Severe Acute Respiratory SyndromeAmerican Journal of Clinical Pathology, 2004
- Neutrophil Extracellular Traps Kill BacteriaScience, 2004
- Systemic Reaction to the Anti–T-Cell Monoclonal Antibody OKT3 in Relation to Serum Levels of Tumor Necrosis Factor and Interferon-αThe New England Journal of Medicine, 1989